Table 2 Cohort Demographics and Outcome
Dog | Signalment | Tumor | Prior Treatment(s) | Status at Enrollment | Study Treatment(s) | Outcome |
|---|---|---|---|---|---|---|
1 | 13.6 yo MC Dachshund mixed breed | ASACA | Surgery, mitoxantrone × 8 | Local recurrence, no metastasis | Carboplatin 250 mg/m2, 250 mg/m2 | SD at Day 21, PD at Day 42 |
2 | 14.7 yo MC Husky | OMM | Surgery, melanoma vaccine, Palladia | Pulmonary metastasis | Carboplatin 300 mg/m2 | Euthanized; decompensated on D3 |
3 | 8.0 yo FS Leonberger | OSA | None | Primary tumor | Carboplatin 300 mg/m2 | Withdrawn at Day 21 without evaluation |
4 | 11 yo MC mixed breed | OMM | None | Local tumor, pulmonary metastasis | Carboplatin 300 mg/m2 | PD at Day 21 |
5 | 4.4yo MC Irish Wolfhound | OSA | Amputation, carboplatin × 2 | Pulmonary metastasis | Doxorubicin 30 mg/m2 | PD at Day 21 |
6 | 12.5yo FS Viszla | Abdominal Myxosarcoma | Surgery | Local recurrence | Doxorubicin 30 mg/m2, 25 mg/m2 | SD at Day 21 SD at Day 42 |
7 | 10.8yo FS Greyhound | OSA | Amputation, carboplatin × 2 | Pulmonary metastasis | Doxorubicin 30 mg/m2, 30 mg/m2 | SD at Day 21 PD at Day 42 |
8 | 7.2 yo MC Greyhound | OSA | Amputation, carboplatin × 3 | Pulmonary metastasis | Doxorubicin 30 mg/m2 | PD at Day 21 |
9 | 10.6 yo FS Husky | OSA | Amputation | Pulmonary metastasis | Doxorubicin 30 mg/m2, 22.7 mg/m2 | SD at Day 21 PD at Day 42 |